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Abstract: The selection of natural and chemical compounds for potential applications in 
new pharmaceutical formulations constitutes a time-consuming procedure in drug 
screening. To overcome this issue, new devices called biosensors, have already 
demonstrated their versatility and capacity for routine clinical diagnosis. Designed to 
perform analytical analysis for the detection of a particular analyte, biosensors based on the 
coupling of proteins to amperometric and optical devices have shown the appropriate 
selectivity, sensibility and accuracy. During the last years, the exponential demand for 
pharmacokinetic studies in the early phases of drug development, along with the need of 
lower molecular weight detection, have led to new biosensor structure materials with 
innovative immobilization strategies. The result has been the development of smaller, more 
reproducible biosensors with lower detection limits, and with a drastic reduction in the 
required sample volumes. Therefore in order to describe the main achievements in 
biosensor fields, the present review has the main aim of summarizing the essential 
strategies used to generate these specific devices, that can provide, under physiological 
conditions, a credible molecule profile and assess specific pharmacokinetic parameters. 
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The biopharmaceutical industry invests a great amount of time and resources in drug discovery and 
development. Devising a process effective in terms of time and cost and that covers the target 
identification and validation of new therapeutic targets, as well as the research of hit and lead 
molecules that could be used as therapeutic agents in clinical treatments, is currently a challenge for 
the drug discovery industry [1,2]. 
The growing number of either synthetic or natural new pharmacological compounds, alongside with 
the knowledge resulting from genomics, which has led to an increasing number of pharmaceutical 
targets without known molecular modulators, has triggered the need for new screening models capable 
of reducing the attrition rates during drug development [1]. Over the past two decades, several 
screening methodology approaches were used, including fragment screening [3], structure-based 
design [4], virtual screening [5] and high-throughput screening (HTS) [2]. 
Presently, most of the screening techniques used to report the binding of the ligand to its receptor 
are based on the measurement of fluorescence (e.g., fluorescence anisotropy [6,7], time resolved 
energy transfer [8], fluorescence correlation spectroscopy [9], fluorescence intensity distribution 
analysis [10]) or scintillation (e.g., scintillation proximity assay [11]). These approaches offer high 
sensitivity with rapid determination of affinity, efficacy and kinetics of drug-receptor interaction [12]. 
However, the required labeling steps represent extra time and cost demands for the process and in 
some cases could interfere with the molecular interaction by the blocking of the binding site, leading to 
false negatives. On the other hand, fluorescent compounds are invariably hydrophobic, and in many 
screens, background binding is a significant problem, leading to false positives [13], so the 
development of platforms with sufficient throughput to be applied in drug discovery and high 
sensitivity in order to provide detailed information about the molecular efficacy and interactions 
without labeling is essential. Also, it is important that such technology be able to determine 
pharmacokinetic parameters, namely in the process of adsorption, distribution, metabolism, excretion 
and toxicity (ADMET) [1]. Over the years, increasing efforts had been made to improve the 
understanding of molecular features that lead to a successful identification of the potential drug 
liabilities by the prediction of human pharmacokinetics. Biosensors are devices composed by two main 
parts: a biological derived sensing element (like enzymes, antibodies, cells and nucleic acids) and a 
physical transducer (e.g., electrochemical, piezoelectric, calorimetric and optical), capable of detecting 
specific analytes in a real-time mode, and converting their presence or concentration into an electric 
readout signal (Figure 1) [14]. Biosensors, in particular the electrochemical and optical biosensors that 
constitute the focus of this review, are advantageous tools for the drug development industry, and can 
be found both in the screening process and in the pharmacokinetics evaluation. Although 
electrochemical and optical biosensors can be used in both applications, is also true that 
electrochemical sensors are predominantly used to detect the drugs and assess their toxicity, whereas 
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optical sensors are used specifically to predict a drug’s pharmacokinetic profile. This review intends to 
illustrate the importance of protein- based biosensors, their accomplishments and future perspectives.  
Figure 1. Operative scheme of a standard biosensor. The biological part is either integrated 
or closely associated with the physical transducer, and behave as a recognition element, 
capable to detect a specific biological analyte. Once the interaction takes place, the 
bio(chemical) signal generated will be converted by a physical transducer in a measurable 
discrete or continuous signal, whose intensity, could be directly or inversely proportional to 
the analyte concentration. 
 
2. Proteins as Biolog ical Recognition Elements 
The selection of the biological recognition elements is a crucial step in a construction of a  
biosensor [15]. The selectivity and specificity of the biosensor depends on the correct selection of the 
biological component that must only interact with the analyte of interest but not with other substances 
present in the target sample [15–17]. Then, the biological element should be capable to detect the 
presence, activity, and quantify a specific analyte in solution [18]. Therefore, is fundamental that the 
assembly process assure the stability and sensitivity of the recognition element. Proteins and enzymes 
are unstable structures that must to be immobilized in order to be used as biosensors. Since the reuse of 
the enzyme is only possible if the activity is retained for several cycles, enzyme stabilization is a 
crucial step [19]. 
Stabilization has been attributed to a rigid conformation of the immobilized biocatalyst, which 
prevents unfolding of enzyme and inactivation of its active site. So, along with stability, 
immobilization also enables the efficient recovery of the enzyme from the reaction environment as 
well as their use in continuous operation [20]. However, a specific immobilization process will not 
always lead to enzyme stabilization.  
There are three major routes for performing immobilization: the binding to a support [21–23], 
encapsulation or entrapment [24] and cross-linking (carrier free) [25]. The main drawbacks and 
advantages of each technique are depicted in Table 1. The immobilization of the enzymes on a support 
may alter its performance in different processes such as: selective hydrolysis or oxidation, kinetic 
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resolution of racemic mixtures or influence the kinetic controlled synthesis [26] In fact, random 
immobilization on a wrong support may produce even a decrease of enzyme stability [19]. For that, 
more demanding technologies like tailor-made heterofunctional supports and site-directed mutagenesis 
are employed. Since they allow control over enzyme immobilization, the orientation of the protein on 
the support surface, and the intensity of enzyme interaction with the support, these techniques have led 
to unprecedented target protein stabilization [20,27]. Furthermore, these new methods can improve the 
activity and even the selectivity of the immobilized protein through directed rigidification of selected 
areas of the protein [28].  
Table 1. Summary of the main advantages and drawbacks of typical immobilization 
methods applied in pharmaceutical fields.  
Method/Binding Nature Advantages Drawbacks 
Adsorption 
Simple and easy;  
Limited loss of protein activity. 
Desorption;  




No diffusion barriers;  
Short response time. 
Coupling with toxic product;  
Random orientation;  
Poor reproducibility. 
Cross-linking Simple technique. High protein activity loss. 
Affinity Interaction 
Perfect control of enzyme orientation 
during immobilization procedure. 
Require the presence of specific 
groups on the enzyme. 
Entrapment 
No chemical reaction between the 
monomer and the enzyme that could 
affect the activity;  
Several types of enzymes can be 
immobilized within the same polymer. 
Enzyme leakage;  
Diffusion Barrier;  
Require high concentration of 
monomer and enzyme in the 
electropolymerization step. 
The selection of an appropriate carrier material, in order to prepare an effective immobilization 
procedure, is also relevant. Nanomaterials, as carriers or entrapment agents are gaining a prominent 
place within immobilization methods, as they offer the possibility of tuning their pore diameters, 
hardness, hydrophobicity/hydrophilicity ratio as well as the control of the magnetic properties and 
conductivity, and thus increase the precision of enzyme immobilization control [20,29]. Nanomaterials 
and nanostructures also generally provide a large surface area and low mass-transfer resistance, which 
enables better interaction with the enzyme, increases immobilization efficiency, and enhances the 
long-term storage and recycling stability of the enzyme [29]. 
In summary, all the previously referred techniques have the same aim, the production of a stable 
layer with an attached biomolecule with sufficient binding sites, capable of maintaining its structure 
and activity to recognizing the target analyte. On the other hand, factors such as accuracy, sensor-to-sensor 
reproducibility and operation lifetime are factors influenced by the stability of the binding between the 
biological recognition element and the transducer. Therefore, the ideal method for a suitable 
immobilization should be a compromise between sensitivity and stability [17,18]. So far, biological 
recognition elements such as enzymes, antibodies, DNA, receptors, organelles, microorganisms, and 
some plant and animal tissues have allowed the detection of a wide range of biological or chemical 
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compounds [30]. In particular, protein-based biosensors have gained applicability in several fields such 
as health care, food safety, environmental monitoring, drug screening, and pharmaceutical studies [31]. 
2.1. Enzymes 
The first proposed biosensors were an enzyme-based device developed by Clark and Lyons in 1962 
to measure glucose levels. Since then, enzyme-based biosensors have seen a massive growth in terms 
of applications [14]. As biological molecules responsible for thousands of metabolic processes, 
enzymes are the oldest and still the most used recognition element in biosensors. Due to their special 
structural active site arrangement, enzymes have an optimum specificity for a substrate molecule, 
having the ability to detect target compounds in a complex mixture [14]. In some cases, enzymes 
incorporate small non-protein chemical groups (e.g., cofactors) into the active site structures, which 
can also help in determination of substrate specificity. Based on catalytic action and binding 
capabilities for specific detection, enzymes provide to the sensor the ability to detect much lower limits 
when compared with other binding techniques [15,16]. However, enzymes are often instable which 
results in a decrease of enzyme activity.  
There are several applications of enzyme-based biosensors as a screening methodology in the 
pharmaceutical industry as shown by Table 2, including the search for new antibiotics and cancer 
therapeutic drugs, among others. An example of the spread and evolution of enzyme-based biosensors 
is the penicillin biosensor [32]. Belonging to the most familiar group of β-lactam antibiotics, penicillin, 
has been used extensively in human medicine to prevent infections caused by bacteria and fungi [33], 
so the determination of different kinds of penicillin and derivatives, is very important in medicine and 
pharmaceutical production (e.g., the drug control analysis of antibiotic tablets, capsules and 
injectables) and this requires a rapid, inexpensive method capable of detecting small amounts of 
penicillin [34]. Based on this idea, Poghossian and co-workers developed a pH-sensing biosensor with 
immobilized penicillinase on its active surface. Penicillinase catalyzes the hydrolysis of penicillin to 
penicillinic acids, which results in a variation of H+ ion concentration, leading to a pH change.  
The result was a biosensor sensitive to penicillin G with a low detection limit of 0.5 µM. Due to the 
introduction of a diffusion barrier, as shown by the group, in a study of penicillin G, ampicillin, and 
amoxicillin, the detection limit could be decreased from 0.1 mM for penicillin G to a lower value of 
0.5 µg of penicillin per analyzed sample [34,35]. More recently, with a layer-by-layer film containing 
single graphene nanosheets, preadsorbed with hematein, ionic liquids and penicillinase, Wu and  
co-workers achieved a low detection limit penicillin biosensor that exhibited excellent performance for 
penicillin in a linear range from 1.25 × 10−13 M to 7.5 × 10−3 M and a incredible detection limit of 
10−13 M [36]. As we can see, when the drugs contain hydrolysable groups, or when there is H+ 
liberation, selective electrodes or potentiometric biosensors, which we will discuss in more detail in 
this review, are the choice. When oxidized drugs are the focus of the study, amperometric tranducers 
and oxidases enzymes such as peroxidases, laccase, tyrosinase, and superoxide dismutase are the 
preferred choice, as shown by Table 2. 
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Table 2. Biosensor performance based on different enzyme immobilization strategies for pharmaceutical applications. 
 Immobilized Technique Analyte Immobilized Enzyme Detection Method Detection Limit Linear Range Sensitivity References 
Adsorption 
Physical Adsorption H2O2 HRP Amperometric 2 μmol∙L−1 8.0 μmol∙L−1 to 3.0 mmol∙L−1 - [37] 
Layer-by-layer Glucose GOD Amperometric 0.20 mmol∙L−1 - 16 µA mmol∙L−1∙cm−2 [38] 
Layer-by-layer Glucose GOD Amperometric 83 µmol/L 0.5 to 5.5 mmol/L - [39] 
Electrochemical doping Choline ChOD Amperometric - 1 × 10−7 to 1 × 10−4 M - [40] 
Lipidic microenvironement Lactase Lactase/GalOD Amperometric - 5.6 × 10−2 to 3.3 × 10−1 - [41] 
Covalent coupling 
 Lactate LDH Amperometric 1 μM 5 to 90 μM 0.0106 μA/μM [42] 
 Dopamine Tyrosinase Amperometric - 5–120 μM - [43] 
 Dopamine Tyrosinase Amperometric - 1–200 µM 232.5 mA∙M−1∙cm−2 [44] 
 Urea Urease Amperometric - 0.16–5.02 μM - [45] 
 Urea Urease Amperometric 0.02 mM 0.1 to 0.7 mM 4.5 µA/mM [46] 
Cross-linking 
 Glucose GOD Amperometric 1 µM 5 × 10−5 to 1.2 × 10−2 M 21.7 A/mM∙cm2 [47] 
 Glucose GOD Amperometric  70–420 mg∙dL−1 - [48] 
 MSG (L-GLOD)/(L-GLDH) Amperometric 0.02 mg/L 0.02 to 1.2 mg/L - [49] 
Affinity 
Biotin/avidin Urea Urease ChemFEC - 10−4 to 10−1 M - [23] 
Chelation Paraoxon AChE Electrochemical 10−12 M 10−8 to 10−13 - [50] 
Entrapment 
Electropolymerization Glucose GOD/HRP Amperometry 3 × 10−5 M (3.00 × 10−5 to 2.43 × 10−3 M 7.01 ± 0.18 μA∙mM−1∙cm−2 [51] 
Photopolymerization Dichlorvos AChE Amperometry 9.6 × 10−11 mol∙L−1 2 × 10−10–1 × 10−8 - [52] 
Silica-sol-gel Glucose GOD Amperometry 50 μM 0.2–20 mM 196 nA/mM [53] 
Polysaccharide-based gel Ethanol ADH Amperometry 0.52 μM - 0.1646 AM−1·cm−2 [54] 
Carbon Paste electrodes Dopamine HRP Amperometry 9.0 × 10−6 mol∙L−1 9.9 × 10−5 to 1.6 × 10−3 mol∙L−1 - [55] 
Agarose Dopamine Tyrosinase Amperometry 9.0 × 10−7 2.0 × 10−6 to 1.0 × 10−5 - [56] 
Sol-gel Xantine XO, SOD and HRP Fluorescence 20 nM 0–3.5 µM - [57] 
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Enzyme-based biosensors could also be found in the search for inhibitors [16]. An example is the 
work performed by Nordin and co-workers. Based on SPR technology and several kinases (serine, 
threonine and tyrosine), information on the relationship between inhibitor structure and function was 
collected [58]. More recently the special catalytic features of the enzymes could be incorporated in 
nucleic acid biosensors to report and detect DNA [59,60]. 
2.2. Antibodies 
Antibodies (Abs) or immunoglobins (Igs) are “Y” shaped glycoproteins capable of recognizing a 
specific antigen. The amino acid sequence in the variable region confers the specificity of the Ab to the 
Ag, and so the established binding is highly specific and selective [61]. For all these features, Abs 
were seen as a good recognition molecule to be used in the construction of a biosensor [62]. 
Despite the fact that the application of immunological compounds as sensing agents was described 
by Yalow and Berson in the 50s [63], it was not until 1987 that Vo-Dinh and co-workers described the 
detection of a chemical carcinogen using an optic-based immunosensor [16]. Based on antigen-antibody 
(Ag-Ab) interactions, where an Ag or an Ab are immobilized on a solid surface [18,63], this device 
could be coupled to a wide variety of transducers to measure the signal resulting from Ag-Ab 
interactions [16,18]. However, the two transduction methods more frequently used in immunosensors 
are the optical and electrochemical ones. The detection can be direct or indirect, meaning that detection 
of Ag-Ab interactions is in real time or it requires a label compound such as an enzyme or a 
fluorescent molecule and a secondary reaction to produce the signal [18,63]. 
The high affinity of Ag-Ab recognition offers a high specificity to the immunosensor [16]. In 
particular, Abs are the critical part in the immunosensor assembly, defining its sensitivity, stability and 
specificity [16,64], so an optimized Ab immobilization procedure allows its orientation in the sensor, 
crucial for maintain its stability and allowing the interaction with the analyte [17]. Nevertheless, an 
adequate sensitivity and reproducibility is only obtained by applying high affinity Abs [18,64]. 
Moreover, the Ag-Ab interaction may be irreversible, which leads to harsh conditions for biosensor 
regeneration [18,64]. Despite this, recombinant Ab and Ab fragments present a viable means to 
overcome some of these drawbacks, improving the immobilization and, as a result, the selectivity and 
stability of immunobiosensors [16].  
2.3. Other Proteins 
Plasma proteins such as human serum albumin (HAS) and α1-acid glycoprotein (AGP), are a class 
of proteins that greatly influence drug distribution. Since the earliest possible ADME data is essential 
for the selection of lead compounds, and as the overwhelming majority of new drugs are intended to be 
administrated orally, an assessment of drug bioavailability is imperative. For instance, high affinity for 
plasma proteins could reduce the free concentration of the drug in the blood stream. Therefore, 
depending on the drug and the target, a high affinity for plasma proteins may consequently be an 
advantage or a drawback for efficacy [65]. Therefore, pharmacokinetic evaluation of new drugs 
through the application of plasma proteins as a biological recognition element and SPR methodology 
were implemented [66,67].  
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HAS, the most abundant protein in blood plasma, serves as a transport protein for numerous 
compounds, especially hydrophobic compounds. The binding of lyophilic drugs to this protein results, 
in some cases, in higher solubility’s and lowers levels of toxicity [65]. In the study performed by 
Frostell-Karlsson and co-workers they determined through a SPR technology the binding affinity of 
HAS to a poll of 19 different drugs; this technology revealed a good correlation with the reported 
binding HAS levels and required a low samples volume [66]. 
As illnesses of the century, cancer and HIV are subject to intense investigation in order to develop 
suitable anticancer chemotherapeutic agents and anti-HIV drugs. For these studies, information about 
absorption or distribution kinetics is required because the data in the literature regarding this set of 
molecules suffers from discrepancies and great variability between assays, which is in part due to the 
complex pharmacokinetics and pharmacodynamics of these classes of molecules [65,68]. To overcome 
these, Cimitan and co-workers proposed a biosensor based on SPR technology and two human plasma 
proteins (HAS, AGP). In this study the knowledge of the drug bound percentage and active drug 
concentration lead to a better understanding of the drug-receptor interaction mechanisms. 
3. The New Era in Biosensors Nanostructures Assembly 
The immobilization process is crucial and could affect the performance of the electron-transfer 
phenomenon, so much attention has been given in the development of new immobilization procedures, 
through the combination of techniques and new materials, in order to obtain a high electron transport 
efficiency between the redox centers of the proteins, and the electrodes, without disrupting the protein 
native structure [69]. Due to their small size, large surface-to-volume ratios and surface activities, 
nanodimensional materials, such as nanoparticles, nanotubes, nanofibers and nanorods, represent a 
promising approach for the construction of biosensing devices [70]. Their unique properties provide a 
suitable environment for protein immobilization, while maintaining their bioactivity, with a great 
enhancement in the analytical performance in terms of detection limits and kinetic profile. 
In general, noble metal nanomaterials (NMNs) display physical and chemical properties like large 
surface area, good surface chemistry properties, and high conductivity, ideal to perform redox 
reactions [71]. These characteristics allow a considerable improvement of the analytical performance, 
leading to lowered detection limits and reduction of deposition time in comparison to conventional 
electrodes. The study developed by Yang and co-workers is a clearly example of the previous statement. 
Through the combination of a platinum nanoparticle-doped sol-gel solution with multi-walled  
carbon nanotubes (CNT) they created a glucose biosensor with low-potential detection of hydrogen 
peroxide (range from 1 to 25 mM), a response time lower than 15 s and a remarkable sensitivity  
(0.98 μA∙mM−1∙cm−2) when compared to the CNT-based biosensor (0.27 μA∙mM−1∙cm−2 at 0.1 V) [72]. 
Another example of this fact is a glucose biosensor proposed by Zhu and co-workers, where glucose 
oxidase (GOD) and HRP were immobilized. This co-immobilization in an electropolymerized pyrrole 
(PPy) film on a single wall carbon nanotubes (SWNT)-coated electrode, producing a bienzymatic 
sensor with lower operational potential (−0.1 V) that led to the preservation of the sensitivity  
(430 ± 13.4 µAM−1∙cm−2) and also minimized the risk of interference by ascorbic acid (AA), uric acid 
(UA) and acetaminophen (AP), usually described as main the interferents in glucose assays. This fact 
is probably due to a direct electron communication bridged established by the carbon nanotubes 
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between HRP and the electrode. The sensor also reveals a linear detection limit range from 0.50 µM to 
1.00 mM for hydrogen peroxidase concentration, and a low detection limit of 0.50 ± 0.14 µM. In terms 
of stability, the biosensor retains 82% and 67% of the initial sensitivity, respectively, after 1 and  
2 weeks of continuous measurements [51]. 
Electrode surfaces modified with self-assembled monolayers (SAMs) of thiols provide a simple 
route to tailored materials that can be further functionalized with AuNPs and enzymes. Gold(Au)NPs 
is another material applied in biosensor constructions. For example, several studies have reported that 
electrodes modified with Au-NPs enable the direct electron transfer from cytochrome c [73], 
myoglobin [74], HRP [75], superoxide dismutase [76] and bilirubin oxidase [77]. More recently, a 
study demonstrated that these modified electrodes could also allow a rapid direct electron transfer 
between laccase and Au-NPs modified electrodes, enabling a more efficient bioelectrocatalytic oxygen 
reduction [78]. Regarding the laccase biosensor, Lanzellotto and co-workers developed a nanostructure 
laccase-based electrochemical biosensor that exploits the beneficial features of functionalized fullerenols 
and AuNPs, such as high surface areas, conductivity, flexibility and reactivity. The results show that the 
assembled nanocomposite material (Au-AuNPs-fullerenols) reveals an enhancement of the electrochemical 
properties, and when immobilized with TvL presents a good stability, a reduction to 87% of the initial 
value of sensitivity after 120 days from preparation, a good reproducibility and an enhancement of the 
bioelectrochemical performance with a lower detection limit of 1.1 mg L−1∙mg∙L−1 [70]. 
Another device that has generated a growing scientific interest is the plasmonic nanostructure. As 
verified by Salamon and co-workers, this structure could be used as a solid-support planar proteolipidic 
membrane, that enables the study of the biochemistry and biophysics of membrane-associated 
receptors and enzymes using surface plasmon resonance (SPR) spectroscopy [79]. This structure has 
also been used for the study of pharmaceutical protein-protein interactions [80]. Therefore, the creation 
of a hybrid system that combines plasmonic nanoparticles with enzymes and at the same time links the 
biological and electronic functions is clearly advantageous. Several studies have verified that the 
previously described combination enhances the performance features of the biosensors, namely their 
sensitivity, selectivity, and limit of detection [81,82]. An example of this approach is the work 
performed by Ren and coworkers with enhancement of the electrocatalytic response of the sensor from 
0.531 µA to 31.17 µA [83]. Also, Abel and collaborators in their study demonstrated that silver island 
films (SIFs), the type of plasmonic nanoparticle, can be incorporated into current enzyme-based 
biosensing applications for the detection of biotinylated compounds, revealing a increasing biosensor 
response [84]. 
4. Biosensosr Based on Transduction 
4.1. Electrochemical Biosensors 
Electrochemical biosensors are the oldest and more applied type, representing more than half of the 
biosensors reported in the literature [15–17]. They provide quantitative and semi-quantitative 
measurements through the use of an electrochemical transducer [14]. Further classified into 
amperometric, potentiometric, impedance, and conductometric sensors, these devices present a  
simple and quick methodology, high sensitivity, low-detection limits and low interferences from the  
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matrix [14,16,17,63]. For all that, electrochemical detection appears to be a suitable option for the 
construction of miniaturized and portable biosensors [63,64]. However, some challenges persist, 
including high performance and cost effectiveness [16], so most recently published research is focused 
on the optimization of the biosensor structure [17]. Improvements in performance and stability have 
included new methodologies for biomolecule immobilization and the application of nanomaterials in 
biosensor construction [31]. 
4.1.1. Amperometric Biosensors 
The amperometric transducer is the most commonly used among electrochemical biosensor  
groups [14,18]. Amperometric biosensors are based on the measurement of the current resulting from 
the electrochemical oxidation or reduction of an electroactive species at a fixed potential, revealing a 
high sensitivity and a wide linear range that can be applied when drugs susceptible to oxidation are the 
subject of evaluation [14,15,18,85]. The majority of the available amperometric biosensors apply 
enzymes as biological recognition element [18,86]. The combination of the high specificity of the 
enzyme for recognizing the analyte with the direct amperometric transduction allows for a fast, simple 
and direct determination of a wide range of metabolites and therapeutic drugs [18]. However, there are 
still some challenges to overcome related to enzyme-based amperometric biosensors, including their 
reduced stability and electrochemical interferences present in complex samples matrices [14,87]. In 
contrast to enzyme-based biosensors, amperometric immunosensors work based in the detection of an 
electrochemical signal, generated from the binding of the antigen and labed antigen to the antibody 
immobilized electrode, that will be amplified by the labeled enzyme in the presence of the enzyme 
substrate, and thus lead to a specific analyte concentration [88]. Several amperometric immunosensors 
for clinical applications have been described [89–91]. However, reductants presents in biological 
liquids could interfere in the signal since they can be also oxidized, so to avoid the high noise signal 
present in these cases, mediators have been developed to shuttle the electrons between the enzyme and 
the electrode. For all that, the labeling amperometric immunosensor display some disadvantages such 
as the loss of the mediators, time-consumption and the need for more reaction steps. Zhang and  
co-workers developed a label-free amperometric biosensor for the detection of methamphetamine 
(MA). In this work, the biosensor was based on Prussian blue (PB), which works as a mediator and as 
an artificial peroxidase. The construct revealed a high selectivity, stability, sensitivity and also a 
decrease in the analytical time reaction with a linear range of 1.0 × 10−8 to 5.0 × 10−6 mol∙L−1 of MA, 
and a detection limit over 7.5 × 10−9 mol∙L−1 [88]. 
Grennan and collaborators described a device based on modified carbon paste screen-printed electrodes 
which enables direct coupling to take place between the redox centers of antigen-labelled HRP and the 
electrode surface. This novel method enables multi-competition analysis of analyte, in real time, on a 
single electrode, presenting a detection limit for atrazine of 0.1 ppb (0.1 µg∙L−1) [92]. Recently, Kim  
and co-workers also developed an immunosensor based on a cadmium sulfide nanoparticles  
modified-dendrimer bonded conducting polymer for the detection of chloramphenicol. The 
immunosensor exhibited a linear range of 50–950 pg/mL and a limit of detection of 45 pg/mL and was 
based on the competitive immune interaction between the free and labeled chloramphenicol for active 
sites of the Ab [93,94]. 
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In the research on anti-inflammatory and analgesic drugs, amperometric biosensors are used 
extensively. For instance, when salicylate is the target, biosensors based on salicylate hydroxylase (SH), 
alone [95] or coupled to other enzymes like glucose oxidase, tyrosinase, hexokinase were proposed [96]. 
As a simple system, based on the SH electropolymerization onto a glassy carbon-working electrode 
with polypyrrole and glutaraldehyde, salicylates could be detect with a linear range between 2.3 × 10−6 
and 1.4 × 10−5 mol∙L−1, where the blood serum samples showed a good correlation comparatively  
with the spectrophotometric method (Trinder) used as reference [95]. However, when a bi or tri 
immobilization was employed, a detection limit of 3.5 × 10−6 M was obtained, demonstrating that  
co-immobilization procedures can improve the sensitivity at lower working potentials [96,97]. 
Sanghavi and co-workers developed a biosensor based on a modified carbon nanotube paste 
electrode for individual and simultaneously determination of acetaminophen (ACOP), aspirin (ASA) 
and caffeine (CF). These led to a biosensor with detection limits of 2.58 × 10−8, 8.47 × 10−8 and  
8.83 × 10−8 M for ACOP, ASA and CF, respectively [98]. Also, for the evaluation of ACOP, another 
amperometric biosensor was developed to detect its presence in three different pharmaceutical 
compositions. This biosensor was based on HRP and revealed a sensitivity of 74.9 mA∙M−1∙cm−2, a 
detection limit of 3.1 × 10−6 M and a linear range from 1.0 × 10−5 to 4.9 × 10−4 M APAP [99]. With the 
same propose, Messina and collaborators developed an on-line microfluidic sensing device with a 
linear range for the detection of paracetamol from 0.35 × 10−6–100 × 10−6 M and a detection limit of 
3.0 × 10−7 M [100]. These recent biosensor models show good detection limit and in the case of the 
biosensor developed by Messina and collaborators, demonstrate the possibility of on-line detection of 
anti-inflammatory drugs without any compromise in the response. 
Another relevant application of electrochemical sensors is new drug screening. This could be 
important in diseases that require the accurate selection of the most effective drug, like Alzheimer’s 
disease (AD). With the purpose of developing a simple drug sensitivity test, Du and collaborators 
developed a biosensor to investigate the efficiency of the inhibition of the activity of immobilized 
AChE by neostigmine and galantamine (drugs associated with AD). The assembled construction 
reveals an amplification of the sensitivity, with better accuracy with other conventional assays [101]. A 
reliable example of the application of these biosensors is based on cytochrome P450 family enzymes  
(CYP 450). The CYP 450 family consists on a group of heme-containing enzymes implicated in the 
metabolism of xenobiotics in the body, which makes them a target in pharmaceutical research for the 
screening of lead compounds in drug development [102]. These systems are characterized by electron 
transfer during substrate conversion and the electrochemistry mechanism underlying the research using 
several metal electrodes (e.g., Au, Pt and Tin oxide) and non-metal electrodes (e.g., glassy carbon, 
pyrolytic graphite, edge-plane graphite and carbon cloth) [103]. In recent years, several CYP enzymes 
such as CYP2B4, CYP1A2 and CYP3A4 have been immobilized for the detection of multiple 
compounds including aminopyrine, benzphetamine, phenobarbital, clozapine, quinidine, nifedipine, 
alosetron, and andondansetron [102]. Panicco and coworkers described a micro-machined eight-electrode 
array for the amperometric measure of KM and kcat values of these phase-1 drug metabolizing 
polymorphic enzymes. In this study, human P450 2D6 and 2C9 were engineered and covalently linked 
to a surface of a modified gold electrode and the results were validated using warfarin and bufuralol, 
which are marker drugs for the 2C9 and 2D6 enzymes, respectively [102,104]. Recently, based on 
CYP 450, Baj-Rossi and collaborators described the characterization of an electrochemical biosensor 
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in order to monitor naproxen. The dynamic linear range for the amperometric detection of naproxen 
had a major and minor detection concentration, respectively, of 300 µM and 16 ± 1 µM, included in 
the physiological range (9–300 µM). This system allows real time naproxen profiling and represents an 
innovative point-of-care solution [105]. 
4.1.2. Potentiometric Biosensors 
Potentiometric biosensors are based on the use of an ion-selective electrode and ion-sensitive field 
effect transistor for obtaining the analytical information. In these sensors, the signal resulting from a 
biorecognition process is converted into a potential measurement to provide an analytical signal [14].  
In addition to the amperometric ones, potentiometric transducers are often used in electrochemical 
biosensors due to their long durability and mechanical stability. Further advantages come from their 
simple instrumentation, low cost, and their ability for continuous monitoring [17]. The lack of 
sensitivity between concentrations within the same order of magnitude and high occurrence of  
non-specific binding effects when compared to amperometric counterparts are some of the major 
drawbacks [14,63]. Another relevant problem with this device is the leaching of the membrane 
components into samples. This can be solved by reducing the electroactive components in polymeric 
membranes [17]. 
Potentiometric biosensors have been used for the detection of compounds of pharmaceutical interest 
for a long time. Ameer and colleagues developed a potentiometric biosensor based on entrapment of a 
tyrosinase into a conducting polypyrrole film on a platinum electrode for the detection of catechols. 
This device presented a sensitivity of 10 mV/µM with a response time of 80 s and the lowest 
detectable concentration was 1.0 µM [106]. More recently, the same research group built and 
compared two electrochemical sensors, a potentiometric and an amperometric device, also based into 
enzyme immobilization via entrapment into polypyrrole films. The co-immobilization of purine 
nucleoside phosphorylase and xanthine oxidase enabled the detection of phosphates with a lower linear 
concentration range and minimum detectable concentration level (20–200 µM, 20 µM) when 
compared to amperometrics (0.1–1 mM) [107]. For the determination of epinephrine, Mataveli and 
coworkers proposed a potentiometric biosensor based on the packaging of a modified carbon paste 
containing a polyphenol oxidase extract into a polyethylene tube. This miniaturized biosensor provide 
a linear range from 8.00 × 10−9 to 8.00 × 10−4 mol∙L−1 for medicine samples and from 8.00 × 10−7 to 
8.00 × 10−3 mol∙L−1 for blood samples [108]. 
Recently, a new approach was developed for the screening and characterization of natural 
compounds that may act as potential competitive reversible inhibitors of acetylcholinesterase (Ach). 
Natural compounds may constitute interesting therapeutic drugs for the treatment of brain diseases as 
Ach inhibitors, due to its role in the termination of impulse transmission in the cholinergic  
synapses through the hydrolysis of acetylcholine. Consequently, the developed method was applied to 
the Ach inhibitor galantamine using an acetylcholine-selective electrode, exhibiting a linear range  
from 2 × 10−8 to 1 × 10−6 M, a limit of detection of 5.4 × 10−9 and inhibition constant KIGal of  
2.0 × 10−7 ± 0.1 × 10−7 M [109].   
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4.2. Optical Biosensors 
Over the last decades, fast and significant advances in instrumentation and experimental design 
have increased the applicability of optical biosensors in many fields, including drug discovery [13,14]. 
Optical biosensors are constituted by a light source that generates light with specific characteristics, a 
modulating agent, a sensing area and a photoreceptor [16]. In general, these sensors can measure 
changes in local refractive index at the sensor surface but, specifically, they can exploit surface 
plasmon resonance, waveguides and resonant mirrors to analyse biomolecular interactions. However, 
most of these biosensors exploit the evanescent waves phenomenon, an electromagnetic field created 
by the total internal reflection of light at a solution-surface interface, to characterize the interaction 
between enzymes/Ab and analyte. Thus, optical sensors enable the determination of the affinity and 
kinetics of a wide variety of molecular interactions in real time, with or without the need for a 
molecular tag or label [13]. 
The amount of information provided by these devices is large, while binding rates and binding 
levels can be interpreted in order to obtain the specificity, kinetics and affinity of the interaction and/or 
analyte concentration. Other advantages are the low signal-to-noise ratios, the low reagent volumes 
required for analysis and, particularly, the possibility of performing real-time analysis [16]. The direct 
optical biosensors, as the name suggests, allow effective real-time analysis without the need of 
labelling the analyte or the enzyme/Ab of complex matrices, avoiding the separation step to remove 
free from bound label [16,18]. However, some optical devices, the indirect biosensors, incorporate 
suitable labels including fluorophores to carry out the analysis [16]. 
4.2.1. Surface Plasmon Resonance Based Biosensors  
Surface Plasmon Resonance (SPR), is an optical phenomenon, applied in biosensor technology that 
occurs as a result of the total internal reflection of monochromatic and polarized light [15]. These 
devices measure in real-time the light absorbed or emitted, as a result of a biological and/or chemical 
reaction, which are related to the quantity of complex formed between the immobilized molecule on 
the sensor surface and a molecule in solution without the need of any labeling [12,14,15,110,111]. 
Through the knowledge of the protein concentration, the percentage of compound bound and half-life 
of the drug can be deduced [13]. As a device that could be applied directly to monitor the binding of 
relatively low molecular weight compounds to immobilized drug targets, with the capacity to provide a 
kinetic data for drug-target (e.g., enzymes, Ab, receptors) interaction, these sensors are extremely 
advantageous in identification, screening and optimization of leading molecules for drug discovery and 
ADME analysis [112]. 
In the case of imunosensors, the stable Ab immobilization via a biotin-avidin interaction or 
covalently via amine, thiol or aldehyde chemistry allows the biosensor regeneration, increasing its 
lifespan (50–100 analytical cycles) [18]. In particular, the Ab immobilization via biotin-avidin appears 
to avoid non-specific avidin adsorptions, increase the storage time of biosensor and enables its 
miniaturization [63]. However, non-specific interactions with the biorecognition elements can be 
verified, which suggests a lack of specificity when compared with indirect optical methods [18]. 
Another concern is its inability to analyze low molecular weight compounds (<500 Da) because, as 
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SPR detects the mass of the analyte, smaller molecules prevent an adequate measurement [15]. 
Nevertheless, improvements in signal-to-noise ratios increased the chances of detection of very small 
analytes [14]. Indeed, Kim and coworkers have described a portable device designed for the detection 
of low molecular weight analytes [63]. 
Several publications have appeared in the last decade describing pharmacological applications of 
SPR methodology. The SPR technology has been increasingly used in the construction and 
development of new biosensors for the assessment of kinetic parameters, including in the recognition 
and stability in a couple of drugs. Many efforts has been made in order to improve the SPR low 
molecular weight drug detection capacity by increasing sensitivity through improvements in hardware, 
software and data evaluation [110]. Based on that, recently we saw the use of such technology as a toll 
in fragment-based drug design [82]. Milkani and coworkers developed a surface plasmon resonance 
sensor capable of directly detecting AChE inhibitors. As referred above, AChE plays an important role 
in Alzheimer’s disease, because its “reversible” inhibition has a great therapeutic potential. In this 
work, the authors used neostigmine and eserine (compounds used in the treatment of the disease) as 
inhibitors, and evaluated their binding affinity (KA) to AChE by observing the changes in the refractive 
index values. The results showed that neostigmine presents a higher affinity (3.8 × 10−3 M−1) than 
eserine (1.7 × 10−3 M−1) for AChE. Also, the results indicated that the modification in the refractive 
index compared with the relatively small molecular weight inhibitors, must be due to a shift in enzyme 
conformation as a result of inhibitor binding in the active site [113]. 
Markgreen and collaborators applied this technology in order to establish a relationship between 
structure and interaction kinetics for HIV-1 protease (retroviral aspartyl protease essential for the  
life-cycle of HIV). For traditional assays HIV-1 protease inhibitors are a challenge, since this enzyme 
is very instable and it is thus difficult to determine the inhibitory constants of the most potent inhibitors. 
However, with SPR technology the association (Kon) and dissociation (Koff) rates for the interaction of 
enzyme-inhibitor can be assessed, and so the equilibrium dissociation constant (Kp = Koff ÷ Kon) can be 
calculated from independent variables. This is corroborated by the results shown for saquinavir.  
As the inhibitor who presents the highest affinity, with a KD of 0.315 ± 7.42 × 10−2 nM, it also  
reveals the lowest dissociation rate constant of all inhibitors analyzed (Koff 2.27 × 10−4 ± 3.04 × 10−5, 
Kon 8.17 × 105 ± 1.61 × 105 M−1∙s−1), which confirms that association and dissociation rates constitute 
an important parameter of drug-target interaction showing that the optimization and screening of 
inhibitor efficacy and potency could be achieved with the information of both high association and low 
dissociation rates rather than by high affinity alone [114]. 
Another example of the application of this technology are the studies involving the kinases family. 
As a molecule that catalyzes the transfer the γ-phosphate group of ATP or GTP to the hydroxyl group 
of serine, threonine, or tyrosine on a substrate protein (often as a response to membrane receptor 
activation), constitutes an important target in drug evaluation once the phosphorylation status of the 
protein is crucial in the cellular signaling cascades. Malfunctions in the process can have pathological 
consequences, such as cancer and inflammatory disease, highlighting the importance of the studies of 
kinases [115]. Nordin and co-workers performed a study where the kinetic profiles of small molecules 
with protein kinases were evaluated, revealing once again that the use of kinetic data directly links a 
modification in structure to changes in recognition (ka), stability (kd), or both, which shows that the 
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affinity differences between the binders could be related either to each rate constant alone or to both 
rate constants concurrently [58]. 
Recently, Das and collaborators constructed a prototype nanoparticle sensor based on Localized 
Surface Plasmon Resonance (LSRP) to detect drug binding on human membrane cytochrome 
P4503A4 (CYP3A4). As it is known, CYP3A4 is one of the most important enzymes in the 
metabolism of xenobiotic drugs. However, it presents a propensity to aggregate and so it becomes 
difficult to study the drug binding in solution and on a specific surface, so the authors developed a 
nanodisk to functionalize and stabilize the monomeric CYP3A4 on Ag nanoparticles. The result was 
the detection of different types of drugs by shifting. As LSR is similar to SPR, the measurement is 
based on the changes in the refractive index, so when the analyte binds to the device, the maximum 
extinction wavelength (λmax) of the nanoparticle shifts [116]. 
Recently, biosensor immunoassays were developed for monitoring chloramphenicol (CAP) 
residues. This study consisted primarily on the screening of anti-CAP Abs to improve biosensor 
specificity and reduce the detection limits using an assay based on the inhibition of the binding of two 
different polyclonal anti-CAP Abs to immobilized CAP on a sensor chip with two different 
immobilization strategies: CAP base surface and CAP surface. The best assay was obtained with Ab 1 
on the CAP base surface due to its very low detection limit (0.1 µg∙L–1) and the decreased consumption 
of Ab, four times less. Then, five different phenicols (chloramphenicol base, chloramphenicol 
succinate, thiamphenicol, florphenicol, chloramphenicol glucuronide) and other commonly used 
antibiotics were tested in order to determine the specificity of the assay [117]. 
4.2.2. Flourescence Based Immunosensors 
Fluorescence protein-based biosensors are highly sensitive tools that allow resolving molecular 
events occurring in only hundreds of milliseconds, demonstrating that information can be transmitted 
through temporal patterns in signaling pathways [118]. In particular, drug discovery is a particular area 
that may benefit from the application of such biosensors. This technique may deepen the knowledge of  
drug-target biomolecule interactions through the study of the mechanisms underlying ligand bias and 
the ability of ligands to selectively stabilize receptor conformations that stimulate or inhibit subsets of 
receptor activities [118]. 
Fluorescence biosensors are constituted by biological or biomimetic recognition elements, where 
one or several fluorescent coupled probes (enzymatically, chemically or genetically), are capable of 
recognizing a specific analyte and the signal generated by this recognition process is transduced into a 
fluorescent signal which can be readily detected and measured [119]. However, the majority of 
analytes and biological sensing elements lack intrinsic fluorescence properties. In this case, the 
interaction of this elements is transduced to an optical signal by coupling fluorescent molecules to 
elements involved in recognition event [14]. The chemical nature and the physicochemical properties 
fluorescent transducer must be taken into account in the design of biosensor in order to obtain an 
optimal signal. Some signals may change depending on the environment conditions, including pH, 
polarity and electrochemical composition. Since the biorecognition event lead to conformation 
rearrangements that produce changes in environment, the fluorophore emits a signal when it sense its 
perturbation or may be quenched when the label is in the proximity of a ligand or another protein. 
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Moreover, the selection of the position to introduce the fluorescent label into the biological recognition 
element is also crucial and should result in a low perturbation of the stability and the recognition event 
and high sensitivity detection. In general, the fluorescent attachment is based in attachment of 
chemical groups and/or in the genetic fusion of green fluorescent proteins (GFP) or derived proteins. 
However, the application of labels through chemical methods have the advantage of introducing the 
label at any position [120]. Regarding the application of enzymes as recognition element, as the 
catalysis is not desirable in some cases, some enzymes have been modified to impair their activity and 
conserve only the ligand binding property [120]. Also, Ab-based fluorescent biosensors are beginning 
to receive attention as suitable biomolecules for diagnostics in homogeneous immunoassays or as 
imaging probes [121]. 
Fluorescent biosensors thus provide a sensitive means of probing ions, metabolites, protein 
biomarkers and other molecules which can be used as therapeutic compounds. Additionally, they can 
provide information about the activity or conformational status of a specific analyte in complex 
matrices such as serum and cell extracts, allowing the monitoring of dynamic processes in a real-time 
mode and the study the behavior of enzymes in terms of function and regulation [119]. The major 
drawback of fluorescence technology are the additional complexity of instrumentation, in either the 
time or frequency domains [14]. 
Calmoduilin (CaM) is a calcium binding proteins that represents an important drug target for many 
drugs including antipsychotic, smooth muscle relaxants, antitumoral and α-adrenergic blocking agents, 
among others [120]. Therefore, CaM has been used as biological recognition element for the design of 
fluorescent biosensors in order to study interactions between this and other molecules, for example, the 
interaction between the CaM coupled to three different fluorophores and phenothiazines and related 
tryclic antidepressants [120]. Recently, a new fluorescent biosensor based on a human CaM (hCaM) 
was constructed for the detection of calcium ion (Ca2+) and CaM inhibitors in solution. The bionsensor 
was applied to analyze the effect of Ca2+ on the binding of trifluoroperazine to CaM, verifying that KD 
ranged from 5.7 ± 0.5 and 0.5 ± 0.07 µM and depends on Ca2+ levels (0–10 µM). Additionally, this 
sensor appears to be suitable for discovering xanthones with anti-CaM properties from the fungus 
Emericella, displaying excellent affinities with KD ranging from 4 to 498 nM [122].  
Cyclin-dependant kinases (CDK/cyclins) are heterodimeric protein kinases that play a central role 
in coordinating cell growth and division. Due to their role in biological systems, CDK/cyclin levels 
and activities are frequently altered in human cancers, contributing to sustain aberrant proliferation in 
cancer cells. So, CDK/cyclins constitute attractive pharmacological targets for the development of 
anti-cancer therapies. CDKACT are activity-based biosensors constituted of a peptide substrate where 
a fluorescent label is coupled to the phosphorylation site and a phosphoaminoacid domain that 
recognizes the phosphorylated peptide sequence. During phosphorylation by active CDK/cyclin 
complexes, CDKACT detects changes in fluorescence intensity, related with kinase activity. Then, it 
allows to monitoring CDK/cyclin activity in real-time, detecting differences in CDK/cyclin activities 
in response to drugs [119]. With respect to immunosensors approaches, Muriano and coworkers 
constructed a fluorescent device based on immobilization of purified IgGs (Ab-143 and Ab-pre) for  
the detection of methylboldenone (MB), an androgenic anabolic steroid. The design of this 
immunosensor is based on two-photon fluorescence spectroscopy coupled to a resonant double grating 
waveguide structure and specific anti-MB abs are immobilized onto a resonant Ta2O5 sensing chip 
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activated with phosphonohexanoic acid spacers. The detection relies on a direct competition using a 
boldenone-rhodamine conjugate as fluorescent competitor, enabling a synthetic steroid detection down 
to 0.1 µg∙L−1 [123]. 
5. Conclusions and Future Perspectives 
Since their first appearance, biosensors have become a widespread technology. First applied in 
routine analysis and diagnosis, they suddenly revealed their potential to enable screening any  
receptor-ligand complex. Also, with the advances in immobilization strategies, alongside with the 
advent of nanomaterials, biosensors will become a more robust and reliable technology. Succinctly and 
until the present, continuous measurement biosensors for the monitor of substances like glucose and 
other endogenous compounds have already been reported. However, few examples are described for 
this application in continuous monitoring of pharmaceutical compounds, with only one enzyme-based 
biosensor reported. The improvements achieved in sensitivity of biosensors through the use of redox 
cycling, are extremely relevant for drug screening analysis, ensuring a better amplification and 
enabling the creation of a next generation of ultrasensitive biosensors. Also, the application of SPR 
technology to biosensors will allow the assessment of kinetic data from compounds binding to specific 
therapeutic targets, yielding new information for the optimization of pharmacological screening. Due 
to its capacity to measure increasingly lower molecular weights, SPR is starting to appear as a tool for 
FBDD, leaving behind the high throughput screening mode. Finally, regarding kinetic studies of 
ADME profiles, up until now few studies were described in the literature. Therefore, further 
investigation in this domain should be performed in order to establish the biosensors as a screen that 
could be applied in all the ADME stages. 
In conclusion, despite the difficulties in achieving reproducibility, stability and sensitivity of these 
types of sensors, all of them have proved to be a useful tools for the pharmaceutical industry in areas 
that encompass almost all stages of the drug discovery process. Thus, it is expected in the next years, 
the availability of an increasing number of devices, upgraded by simple and low cost methods, will 
allow the discover of new therapeutic agents. 
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